azacitidine · Medicine question

Which adults with myelodysplastic syndromes are eligible for azacitidine (Vidaza) treatment?

Name: Which adults with myelodysplastic syndromes are eligible for azacitidine (Vidaza) treatment?
Published: 2026-11-08T13:42:04.202Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Azacitidine (Vidaza) is indicated for adults ineligible for haematopoietic stem cell transplantation who have intermediate-2 or high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS).

Sources for this answer

Vidaza 25 mg/ml powder for suspension for injectionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.1 Therapeutic Indications · Version 25Document updated 19 December 2023

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about azacitidine